<DOC>
	<DOCNO>NCT00300586</DOCNO>
	<brief_summary>The objective trial improve duration control disease PS 0-1 patient progress first-line cisplatin-gemcitabine chemotherapy . Standard therapy patient stop first-line chemotherapy 4 6 cycle begin second-line chemotherapy progression disease occur . Two approach experiment trial attempt prolong progression free survival : - Maintenance chemotherapy single-agent gemcitabine continue till disease progression toxicity . - Sequential treatment erlotinib immediately give end first-line chemotherapy .</brief_summary>
	<brief_title>IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically document NSCLC ( tumor tissue sample provide look assessment EGFR status CISH , immunochemistry mutation ) : adenocarcinoma , squamous cell carcinoma , large cell carcinoma . A cytological documentation NSCLC accept . Stage IV disease metastatic relapse previously irradiate area NSCLC previously treat surgery radiation therapy ( histologically document proof relapse ) stage III B document pleural involvement . Measurable disease accord RECIST criterion . Prior radiotherapy authorize except irradiation concern measurable disease . Age &gt; 18 &lt; 70 year . PS &lt; 2 . Normal hepatic function : serum bilirubin &lt; 1.5 ULN , SGOT ( ASAT ) SGPT ( ALAT ) &lt; 2,5 ULN ; presence liver metastasis , SGOT SGPT must &lt; 5 x ULN . Creatinine clearance &gt; 60 mL/min . Granulocyte count &gt; 1,5 giga/L , platelet count &gt; 100 giga/L . Life expectancy &gt; 12 week . Written ( sign ) inform consent use tumor sample . Written ( sign ) inform consent participate sudy . Small cell lung cancer , bronchioloalveolar carcinoma , neuroendocrine carcinoma . PS &gt; 1 . Prior chemotherapy cisplatingemcitabine . Prior therapy EGFR inhibitor ( e.g . monoclonal antibody ) . No concomitant therapy phenytoin , carbamazepine , rifampicine phenobarbital . Concomitant radiotherapy except localized bone irradiation . Symptomatic brain metastasis . Superior vena cava syndrome . Any unstable systemic disease : significant cardiovascular disease include myocardial infarction within previous year , active infection , significant hepatic renal disease . Preexisting interstitial lung disease . Any inflammatory change surface eye . Psychiatric disease inability understand study comply followup procedure . Grade &gt; = 2 peripheral neuropathy . Any malignancy within 5 year ( except treat carcinoma situ cervix basal cell skin cancer ) . Pregnant lactating woman ; patient reproductive potential must use effective contraception . Inability comply followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Non-small cell lung cancer ;</keyword>
	<keyword>metastatic ;</keyword>
	<keyword>chemotherapy ;</keyword>
	<keyword>erlotinib</keyword>
</DOC>